Preview

Российский журнал детской гематологии и онкологии (РЖДГиО)

Расширенный поиск

Синдром опсоклонус-миоклонус и нейробластома (обзор литературы)

https://doi.org/10.17650/2311-1267-2014-0-1-62-69

Полный текст:

Аннотация

Синдром опсоклонус-миоклонус (ОМС) является редким неврологическим синдромом. Длительное существование неврологических симптомов у пациентов без должного проведенного обследования и лечения, ошибки в диагнозе при первичном обращении больных свидетельствуют о том, что большинство врачей не осведомлены о данном синдроме и критериях его диагностики. Педиатр, который наблюдает ребенка раннего возраста с мозжечковой атаксией, должен знать о том, что это состояние может быть проявлением ОМС. С нейробластомой (НБ) ассоциированы 50 % случаев ОМС, развившегося в детском возрасте. Однако до настоящего времени возникают трудности в ранней диагностике этого состояния, определении объема инициального обследования и тактики терапии. В данной статье приведен обзор литературы, посвященный различным аспектам патогенеза, диагностики, клиники, лечения и прогноза при ОМС. Отдельно рассмотрены вопросы, посвященные ОМС, ассоциированному с НБ.

Об авторах

Д. Ю. Качанов
ФГБУ ФНКЦ ДГОИ им. Дмитрия Рогачева Минздрава России
Россия
Москва


Татьяна Викторовна Шаманская
ФГБУ ФНКЦ ДГОИ им. Дмитрия Рогачева Минздрава России
Россия
Москва


О. Б. Малевич
ФГБУ ФНКЦ ДГОИ им. Дмитрия Рогачева Минздрава России
Россия
Москва


С. Р. Варфоломеева
ФГБУ ФНКЦ ДГОИ им. Дмитрия Рогачева Минздрава России
Россия
Москва


Список литературы

1. Kinsbourn М. Myoclonic encephalopathy of Infants. J Neurol Neurosurg Psychiatr 1962;25:271.

2. Rothenberg A. B., Berdon W. E., D’Angio G. J. et al. The association between neuroblastoma and opsoclonus-myoclonus syndrome: a historical review. J Springer 2009;39:723–6.

3. Pang K. K., de Sousa C., Lang B., Pike M. G. A prospective study of the presentation and management of dancing eye syndrome / opsoclonus-myoclonus syndrome in the UK. Eur J Paediatr Neurol 2010;14(2):156–61.

4. Bataller L., Graus F., Saiz A., Vilchez J. J. Spanish Opsoclonus-Myoclonus Study G. Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonusmyoclonus. Brain 2001;124(Pt 2):437–43.

5. Blaes F., Jauss M., Kraus J. et al. Adult paraneoplastic opsoclonus-myoclonus syndrome associated with antimitochondrial autoantibodies. J Neurol Neurosurg Psychiatry 2003;74(11):1595–6.

6. Giometto B., Taraloto B., Graus F. Autoimmunity in paraneoplastic neurological syndromes. Brain Pathol 1999;9(2):261–73.

7. Buckanovich R. J., Posner J. B., Darnell R. B. et al. Nova, the paraneoplastic Ri antigen, is homologous to an RNAbinding protein and is specifically expressed in the developing motor system. Neuron 1993;11(4):657–72.

8. Grant R., Graus F. Paraneoplastic movement disorders. Mov Disord 2009;24(12):1715–24.

9. Darnell R. B., Posner J. B. Paraneoplastic syndromes involving the nervous system. N Engl J Med 2003;349:1543–54.

10. Titulaer M. J., Soffietti R., Dalmau J. et al. European Federation of Neurological Societies. Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol 2011;18(1):19–e3.

11. Fitzpatrick A. S., Gray O. M., McConville J., McDonnell G. V. Opsoclonusmyoclonus syndrome associated with benign ovarian teratoma. Neurology 2008;70(15):1292–3.

12. Pranzatelli M. R. The neurobiology of the opsoclonus-myoclonus syndrome. ClinNeuropharmacol 1992;15:186–228.

13. Tate E. D., Allison T. J., Pranzatelli M. R., Verhulst S. J. Neuroepidemiologic trends in 105 US cases of pediatric opsoclonusmyoclonus syndrome. J Pediatr Oncol Nurs 2005;22(1):8–19.

14. Gorman M. P. Update on diagnosis, treatment, and prognosis in opsoclonusmyoclonus-ataxia syndrome. Curr Opin Pediatr 2010;22:745–50.

15. Brunklaus A., Pohl K., Zuberi S. M., de Sousa C. Investigating neuroblastoma in childhood opsoclonus-myoclonus syndrome. Arch Dis Child 2012;97(5):461–3.

16. Pike M. Opsoclonus-myoclonus syndrome. Handb Clin Neurol 2013;112:1209–11.

17. Hero B., Schleiermacher G. Update on pediatric opsoclonus myoclonus syndrome. Neuropediatrics 2013;44:324–9.

18. Krasenbrink I., Fühlhuber V., Juhasz-Boess I. et al. Increased prevalence of autoimmune disorders and autoantibodies in parents of children with opsoclonusmyoclonus syndrome (OMS). Neuropediatrics 2007;38(3):114–6.

19. Hero B., Radolska S., Gathof B. S. Opsomyoclonus syndrome in infancy with or without neuroblastoma is associated with HLA DRB1 01 (abstr.). Ped Blood Cancer 2005:45.

20. Raffaghello L., Fühlhuber V., Bianchi G. et al. Role of BAFF in Opsoclonus-Myoclonus syndrome, a bridge between cancer and autoimmunity. J Leukoc Biol 2013;94(1):183–91.

21. Pranzatelli M. R., Tate E. D., Hoefgen E. R. et al. Therapeutic down-regulation of central and peripheral

22. B-cell-activating factor (BAFF) production in pediatric opsoclonus-myoclonus syndrome. Cytokine 2008;44:26–32.

23. Raffaghello L., Conte M., De Grandis E., Pistoia V. Immunological mechanisms in opsoclonus-myoclonus associated neuroblastoma. Eur J Paediatr Neurol 2009;13:219–23.

24. Fühlhuber V., Bick S., Kirsten A. et al. Elevated B-cell activating factor BAFF, but not APRIL, correlateswith CSF cerebellar autoantibodies in pediatric opsoclonusmyoclonus syndrome. J Neuroimmunol 2009;210(1–2):87–91.

25. Pranzatelli M. R., Tate E. D., McGee N.R. et al. BAFF / APRIL system in pediatric OMS: relation to severity, neuroinflammation, and immunotherapy. J Neuroinflammation 2013;10:10.

26. Pranzatelli M. R., Travelstead A. L., Tate E. D. et al. CSF B-cell expansion in opsoclonus-myoclonus syndrome: a biomarker of disease activity. Mov Disord 2004;19(7):770–7.

27. Kirsten A., Beck S., Fuhlhuber V. et al. New autoantibodies in pediatric opsoclonus myoclonus syndrome. Ann N Y Acad Sci2007;1110:256–60.

28. Fisher P. G., Wechsler D. S., Singer H. S. Anti-Hu antibody in a neuroblastoma-associated paraneoplastic syndrome. Pediatr Neurol 1994;10(4):309–31.

29. Antunes N. L., Khakoo Y., Stram D. O. et al. Antineuronal antibodies in patients with neuroblastoma (NBT) and paraneoplastic opsoclonus-myoclonus (POM). J Pediatr Hematol Oncol 2000;22:315–20.

30. Rudnick E., Khakoo Y., Antunes N. L. et al. Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and atineuronal antibodies – a report from the Children’s Cancer Group Study. Med Pediatr Oncol 2001;36:612–22.

31. Connolly A. M., Pestronk A., Mehta S. et al. Serum autoantibodies in childhood opsoclonus-myoclonus syndrome: an analysis of antigenic targets in neural tissues. J Pediatr 1997;130:878–84.

32. Noetzel M. J., Cawley L. P., James V. L. et al. Anti-neuroflament protein antibodies in opsoclonus-myoclonus. J Neuroimmunol 1987;15:137–45.

33. Aydin G. B., Kutluk M. T., Buyukpamukcu M. et al. Neurological complications of neuroblastic tumors: experience of a single center. Childs Nerv Syst 2010;26:359–65.

34. Plantaz D., Michon J., Valteau-Couanet D. et al. Opsoclonus-myoclonus syndrome associated with non-metastatic neuroblastoma. Long-term survival. Study of the French Society of Pediatric Oncologists. Arch Pediatr 2000;7(6):621–8.

35. De Grandis E., Parodi S., Conte M. et al. Long-term follow-up of neuroblastoma-associated opsoclonus-myoclonus-ataxia syndrome. Neuropediatrics 2009;40:103–11.

36. Pranzatelli M. R., Tate E. D., Shenoy S., Travelstead A. L. Ofatumumab for a rituximab-allergic child with chronicrelapsing paraneoplastic opsoclonusmyoclonus. Pediatr Blood Cancer 2012;58(6):988–91.

37. Cooper R., Khakoo Y., Matthay K. K. et al. Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: histopathologic features – a report from the Children’s Cancer Group. Med Pediatr Oncol 2001;36:623–9.

38. Hiyama E., Yokoyama T., Ichikawa T. et al. Poor outcome in patients with advanced stage neuroblastoma and coincident opsomyoclonus syndrome. Cancer 1994;74:1821–6.

39. Biasotti S., Garaventa A., Villavecchia G. P. et al. False-negative metaiodobenzylguanidine scintigraphy at diagnosis of neuroblastoma. Med Pediatr Oncol 2000;35(2):153–5.

40. Krug P., Schleiermacher G., Michon J. et al. Opsoclonus-myoclonus in children associated or not with neuroblastoma. Eur J Paediatr Neurol 2010;14(5):400–9.

41. Mutch L. S., Johnston D. L. Late presentation of opsoclonus-myoclonus-ataxia syndrome in a child with stage 4S neuroblastoma. J Pediatr Hematol Oncol 2005;27(6):341–3.

42. Russo C., Cohn S. L., Petruzzi M. J., de Alarcon P. A. Long-term neurologic outcome in children with opsoclonusmyoclonus associated with neuroblastoma: a report from the Pediatric Oncology Group. Med Pediatr Oncol 1997;28:284–8.

43. Altman A. J., Baehner R. L. Favorable prognosis for survival in children with coincident opso- myoclonus and neuroblastoma. Cancer 1976;37:846–52.

44. Koh P. S., Raffensperger J. G., Berry S. et al. Long-term outcome in children with opsoclonus-myoclonus and ataxia and coincident neuroblastoma. J Pediatr 1994;125:712–6.

45. Мументалер M., Бассетти К., Дэтвалйлер К. Дифференциальный диагноз в неврологии. М.: Медпресс-информ, 2012. С. 318–319.

46. Herman Т. E., Siegel M. J. Ataxia without opsoclonus: right lumbal sympathetic trunk neuroblastoma. Clin Pediatr 2009;48:336–42.

47. Аркайди Ж. Заболевания нервной системы у детей. Под ред. акад. РАМН, д.м.н. А. А. Скоромца. Том 1. М.: Бином, 2013. С. 507–509.

48. Pranzatelli M. R., Tate E. D., Galvan I., Wheeler A. A controlled pilot study of piracetamfor pediatric opsoclonusmyoclonus. Clin Neuropharmacol 2001;24:352–7.

49. Parisi M. T., Hattner R. S., Matthay K. K. et al. Optimized diagnostic strategy for neuroblastoma in opsoclonus-myoclonus. J Nucl Med 1993;34(11):1922–6.

50. Telander R. L., Smithson W. A., Groover R. V. Clinical outcome in children with acute cerebellar encephalopathy and neuroblastoma. J Pediatr Surg 1989;24:11–4.

51. Pohl K. R., Pritchard J., Wilson J. Neurological sequelae of the dancing eye syndrome. Eur J Pediatr 1996;155:237–44.

52. Petruzzi M. J., De Alarcon P. A. Neuroblastoma-associated opsoclonusmyoclonus treated with intravenously administered immune globulin G. J Pediatr 1995;127:328–32.

53. Borgna-Pignatti C., Balter R., Marradi P., Colamaria V. Treatment with intravenously administered immunoglobulins of the neuroblastoma-associated оpsoclonusmyoclonus. J Pediatr 1996; 129:179–80.

54. Wilken B., Baumann M., Bien C. G. et al. Chronic relapsing opsoclonus-myoclonus syndrome: combination of cyclophosphamide and dexamethasone pulses. Eur J Paediatr Neurol 2008;12:51–5.

55. Institut Curie. Opsoclonus Myoclonus Syndrome / Dancing Eye Syndrome (OMS / DES) in Children With and Without Neuroblastoma (NBpos and NBneg) Opsoclonus Myoclonus Syndrome / Dancing Eye Syndrome (OMS / DES) in Children With and Without Neuroblastoma (NBpos and NBneg). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2013 Jun 20]. Available from: http://clinicaltrials.gov / ct2 /show / NCT01868269 NLM Identifier: NCT01868269.

56. Children’s Oncology Group. National Cancer Institute (NCI). Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2013 Jun 20]. Available from: http://clinicaltrials.gov / ct2 / show / NCT00033293 NLM Identifier: NCT00033293.

57. Pranzatelli M. R., Travelstead A. L., Tate E. D. et al. B- and T-cell markers in opsoclonus-myoclonus syndrome: immunophenotyping of CSF lymphocytes. Neurology 2004;62:1526–32.

58. Скворцов И. А. Неврология развития. М.: Литтера, 2008. С. 437–443.

59. Brunklaus A., Pohl K., Zuberi S. M., de Sousa C. Outcome and prognostic features in opsoclonus-myoclonus syndrome from infancy to adult life. Pediatrics 2011;128(2):338–94.


Для цитирования:


Качанов Д.Ю., Шаманская Т.В., Малевич О.Б., Варфоломеева С.Р. Синдром опсоклонус-миоклонус и нейробластома (обзор литературы). Российский журнал детской гематологии и онкологии (РЖДГиО). 2014;(1):62-69. https://doi.org/10.17650/2311-1267-2014-0-1-62-69

For citation:


Kachanov D.Y., Shamanskaya T.V., Malevich O.B., Varfolomeeva S.R. Opsoclonus-myoclonus syndrome and neuroblastoma (a review of literature). Russian Journal of Pediatric Hematology and Oncology. 2014;(1):62-69. (In Russ.) https://doi.org/10.17650/2311-1267-2014-0-1-62-69

Просмотров: 1072


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2311-1267 (Print)
ISSN 2413-5496 (Online)